全髋关节置换术后延迟至术后第1天启用阿哌沙班或利伐沙班与出血减少相关
该研究基于大型全国数据库纳入2015至2023年112555例初次全髋关节置换(THA)患者,比较术后第0天与第1天启用阿哌沙班或利伐沙班的90天出血与血栓栓塞并发症。结果显示第1天启用者急性贫血与总体出血并发症风险更低,且深静脉血栓(DVT)与肺栓塞风险未增加。
要点
- THA术后第1天启用阿哌沙班或利伐沙班与急性贫血和总体出血并发症风险降低相关。
- 延迟至术后第1天用药未观察到DVT或肺栓塞风险增加。
- 利伐沙班组中29.7%在术后第0天用药,阿哌沙班组中26.6%在术后第0天用药。
核心结论
- 择期THA术后将阿哌沙班或利伐沙班延迟至术后第1天启用,与术后贫血风险降低相关,且未增加血栓栓塞并发症风险。
研究设计与样本
- 使用大型全国数据库识别2015至2023年所有初次THA患者,共112555例。
- 利伐沙班组58281例中17288例(29.7%)术后第0天用药、40993例(70.3%)第1天用药;阿哌沙班组54274例中14414例(26.6%)第0天用药、39860例(73.4%)第1天用药。
- 比较各药物术后第0天与第1天启用者90天出血并发症(如急性贫血、输血、血肿、出血)及血栓栓塞并发症(如DVT和肺栓塞),采用单变量分析和多变量回归评估差异。
主要发现
- 第1天启用利伐沙班者急性贫血风险降低(aOR 0.868,95%CI 0.832至0.905,P<0.001)。
- 第1天启用阿哌沙班者急性贫血风险降低(aOR 0.771,95%CI 0.735至0.809,P<0.001)。
- 第1天启用利伐沙班者总体出血并发症风险降低(aOR 0.867,95%CI 0.832至0.903,P<0.001)。
- 第1天启用阿哌沙班者总体出血并发症风险降低(aOR 0.767,95%CI 0.732至0.804,P<0.001)。
- 两种药物第1天启用与第0天启用相比,均未与DVT或肺栓塞风险增加相关。
临床怎么用
- 对择期THA患者,可考虑将阿哌沙班或利伐沙班起始时间安排在术后第1天,以降低出血风险而不增加血栓栓塞风险。
- 具体用药时机仍需结合患者个体出血与血栓风险进行判断。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal timing for initiation of anticoagulation using direct oral anticoagulants following total hip arthroplasty (THA) remains a subject of debate. While direct oral anticoagulants are effective prophylactic agents against venous thromboembolism (VTE), bleeding risks remain a concern. This study sought to compare the incidence of postoperative bleeding and thromboembolic complications following elective THA between patients receiving either apixaban or rivaroxaban on postoperative day (POD) zero versus one. METHODS: A large national database was used to identify all patients who underwent primary THA between 2015 and 2023. Patients receiving either apixaban or rivaroxaban on POD zero were compared to patients who received the same anticoagulant on POD 1. The 90-day post-operative bleeding complications (e.g., acute anemia, transfusion, hematoma, and hemorrhage), as well as thromboembolic complications (e.g., deep venous thrombosis [DVT] and pulmonary embolism), were compared between the POD zero and one cohorts for each medication. Univariable analysis and multivariable regression were used to assess differences. In total, 112,555 primary THA patients were identified. Of the 58,281 rivaroxaban patients, 17,288 (29.7%) received anticoagulation on POD zero compared to 40,993 (70.3%) on POD one. Of the 54,274 patients receiving apixaban, 14,414 (26.6%) received anticoagulation on POD zero compared to 39,860 (73.4%) on POD one. RESULTS: For both cohorts, patients receiving anticoagulation beginning on POD one had a reduced risk of acute anemia (rivaroxaban: adjusted odds ratio [aOR] 0.868, 95% CI [confidence interval]: 0.832 to 0.905, P < 0.001 | apixaban: aOR 0.771, 95% CI: 0.735 to 0.809, P < 0.001) and aggregate bleeding complications (rivaroxaban: aOR 0.867, 95% CI: 0.832 to 0.903, P < 0.001 | apixaban: aOR 0.767, 95% CI: 0.732 to 0.804, P < 0.001). Neither drug was associated with an increased risk of DVT or pulmonary embolism when administered on POD one versus POD zero. CONCLUSIONS: Delayed administration of apixaban and rivaroxaban until POD one was associated with a reduced risk of postoperative anemia without an increased risk of thromboembolic complications in patients undergoing THA.
引用
- Culler MW, Lim MA, Telang SS, et al. Delayed Administration of Apixaban and Rivaroxaban is Associated with Reduced Rates of Postoperative Bleeding Without Increasing Thromboembolic Risk Following Elective Total Hip Arthroplasty. J Arthroplasty. 2026. PMID: 42001913. doi:10.1016/j.arth.2026.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。